JP2020528903A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528903A5
JP2020528903A5 JP2020503928A JP2020503928A JP2020528903A5 JP 2020528903 A5 JP2020528903 A5 JP 2020528903A5 JP 2020503928 A JP2020503928 A JP 2020503928A JP 2020503928 A JP2020503928 A JP 2020503928A JP 2020528903 A5 JP2020528903 A5 JP 2020528903A5
Authority
JP
Japan
Prior art keywords
subject
composition according
minutes
tpo mimetic
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020503928A
Other languages
English (en)
Japanese (ja)
Other versions
JP7481252B2 (ja
JP2020528903A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/043821 external-priority patent/WO2019023418A1/en
Publication of JP2020528903A publication Critical patent/JP2020528903A/ja
Publication of JP2020528903A5 publication Critical patent/JP2020528903A5/ja
Application granted granted Critical
Publication of JP7481252B2 publication Critical patent/JP7481252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020503928A 2017-07-26 2018-07-26 標的放射線治療誘発性血管完全性を保護する方法 Active JP7481252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762537049P 2017-07-26 2017-07-26
US62/537,049 2017-07-26
PCT/US2018/043821 WO2019023418A1 (en) 2017-07-26 2018-07-26 METHODS FOR PROTECTING VASCULAR INTEGRITY INDUCED BY TARGETED RADIOTHERAPY

Publications (3)

Publication Number Publication Date
JP2020528903A JP2020528903A (ja) 2020-10-01
JP2020528903A5 true JP2020528903A5 (enExample) 2021-08-19
JP7481252B2 JP7481252B2 (ja) 2024-05-10

Family

ID=63165522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020503928A Active JP7481252B2 (ja) 2017-07-26 2018-07-26 標的放射線治療誘発性血管完全性を保護する方法

Country Status (11)

Country Link
US (1) US12251424B2 (enExample)
EP (1) EP3658191A1 (enExample)
JP (1) JP7481252B2 (enExample)
KR (1) KR102688415B1 (enExample)
CN (1) CN111432845B (enExample)
AU (1) AU2018306329B8 (enExample)
BR (1) BR112020001367A2 (enExample)
CA (1) CA3070442A1 (enExample)
IL (1) IL272213A (enExample)
PH (1) PH12020500166A1 (enExample)
WO (1) WO2019023418A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54820A (fr) * 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
CN113402614A (zh) * 2021-04-22 2021-09-17 山东泉港药业有限公司 血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用
EP4525907A2 (en) * 2022-05-20 2025-03-26 JANSSEN Pharmaceutica NV Methods for mitigating lung injury in conjunction with exposure to radiation and/or radiation or radiomimetic treatments
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure
WO2025002113A1 (zh) * 2023-06-26 2025-01-02 上海济煜医药科技有限公司 一种人血小板生成素受体激动剂的融合蛋白

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
CN1966520B (zh) 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1542714T3 (da) 2002-09-18 2014-05-26 Janssen Pharmaceuticals Inc Fremgangsmåder til forøgelse af produktion af blodplader og hæmatopoietiske stamceller
RS20060141A (sr) 2003-08-28 2008-08-07 Ortho-Mcneil Pharmaceutical Inc., Peptidi i jedinjenja koja se vežu za receptor
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US20060210542A1 (en) 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
PT1984014E (pt) 2006-02-14 2014-11-13 Janssen Pharmaceutica Nv Utilização de compostos de péptidos tpo e composições farmacêuticas no tratamento da anemia
CN100391474C (zh) * 2006-06-13 2008-06-04 卢建军 用于治疗血小板减少的注射用药物
JP2010511631A (ja) 2006-12-01 2010-04-15 ステイテジックス・インコーポレイテッド トロンボポエチン擬態物
WO2009114725A2 (en) 2008-03-12 2009-09-17 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
KR20110015448A (ko) 2008-06-03 2011-02-15 얀센 파마슈티카 엔.브이. 암 치료와 관련된 혈액 질환을 예방하기 위한 tpo 모방 펩티드
MX2011008936A (es) 2009-02-24 2011-09-21 Alexion Pharma Inc Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
JP2012250880A (ja) 2011-06-03 2012-12-20 Semiconductor Energy Lab Co Ltd グラフェン、蓄電装置および電気機器
US20140047572A1 (en) 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US20140051631A1 (en) 2012-08-17 2014-02-20 Francoise Porteu Pharmaceutical composition comprising tpo or an agonist of the tpo receptor
JP6150374B2 (ja) * 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法
US20200237872A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
MA54820A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques

Similar Documents

Publication Publication Date Title
King et al. Use of amifostine for cytoprotection during radiation therapy: a review
JP2020519295A5 (enExample)
JP2018502120A5 (enExample)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2017521486A5 (enExample)
JP2016536286A5 (enExample)
JP2016532722A5 (enExample)
JP2017538680A5 (enExample)
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
JP2016074664A5 (enExample)
JP2018138578A5 (enExample)
JP2016516073A5 (enExample)
JP2017523184A5 (enExample)
JP2013501816A5 (enExample)
IL308807B2 (en) Combination therapy for treating cancer
JP2017529382A5 (enExample)
JP2017530130A5 (enExample)
JP2021530541A5 (enExample)
JP2019516739A5 (enExample)
JP2021514661A5 (enExample)
JP2019506392A5 (enExample)
JP2018524306A5 (enExample)
CA2689664A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
JP2018509423A5 (enExample)
JP2016515137A5 (enExample)